Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Summary

Eton Pharmaceuticals licensed U.S. rights to ASN-001 (timolol topical gel), a late-stage product candidate for treating proliferating superficial infantile hemangiomas, from Auson Pharmaceuticals. The deal expands Eton's rare disease franchise focused on infantile hemangioma treatments.